New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression

NEXT STORY
Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments
PREV STORY
Sharps Compliance Reports Fiscal 2021 First Quarter Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

CytomX Therapeutics Announces Third Quarter 2016 Financial Results and Provides Pipeline Update

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), ...

author_avatar
NASDAQ Market News

Potential Sequential Revenue Run-Rate Growth of 30% over Q1, based on Preliminary April Results

Revenue growth accelerating as new sales initiatives and expanded team gain tractionNEW HAVEN, Conn., ...

author_avatar
NASDAQ Market News

Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Year End 2015 Financial Results

SOLANA BEACH, Calif., March 04, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a ...

author_avatar
NASDAQ Market News